|Bid||2.56 x 1100|
|Ask||2.59 x 900|
|Day's Range||2.57 - 2.72|
|52 Week Range||1.96 - 16.90|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.50|
On a per-share basis, the Vancouver, British Columbia-based company said it had net income of 12 cents. The drugmaker posted revenue of $25 million in the period. The company's shares closed at $3.07. ...
VANCOUVER, British Columbia, Aug. 08, 2018-- Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood ...
HENDERSON NV / ACCESSWIRE / July 24, 2018 / BioRestorative Therapies, Inc. (BRTX) is a small stem cell company, that has came across our radar screen. Just a few years ago BRTX was trading as high as $10 plus per share, and a high of $3.75 this year alone. Over the last few weeks interest in BRTX has been climbing, and the company has done higher volume days recently than ever before in BRTX trading history.
Stock Research Monitor: PRGO, RHE, and AMRX LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AQXP sign up now at www.wallstequities.com/registration . On Monday, July 23, 2018, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.
Today, Aquinox (AQXP) announced that its late-stage investigational drug, the once-daily oral therapy rosiptor, failed to demonstrate a statistically significant benefit over placebo for IC (interstitial cystitis) or BPS (bladder pain syndrome) in the Phase 3 LEADERSHIP 301 clinical trial. Pursuant to this announcement, Aquinox stock crashed from $15.31 yesterday to $2.43 this morning. Aquinox may have to forego a $25 million of upfront payment, $60 million of development milestone payments, and $70 million of commercial milestone payments that it would have otherwise received based on its exclusive licensing agreement with Astellas Pharma.
plummeted more than 80% Wednesday after late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients. "We will be halting all further development of rosiptor," David Main, CEO of Aquinox, said in a conference call Wednesday morning. The company will also stop administering rosiptor in its trial with patients afflicted with chronic prostatitis because Aquinox does not think it will benefit them in any way, Main said.
Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent. "We will be undertaking a thorough evaluation of our pipeline and other strategic options available to the company," Chief Executive Officer David Main said in a statement. Bladder pain syndrome, or interstitial cystitis, is a chronic condition characterized by bladder pressure, bladder pain and pelvic pain.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 62 cents. Aquinox shares have climbed 11 percent since the beginning of the year. The stock has fallen 6.5 percent ...
The most recent earnings announcement Aquinox Pharmaceuticals Inc’s (NASDAQ:AQXP) released in December 2017 suggested company earnings became less negative compared to the previous year’s level – great news for investorsRead More...
Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access ...
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 69 cents. For the year, the company reported that its loss widened to $50.2 million, or $2.14 per share. Aquinox ...